Institution Directory

Clinical trials at Duke University Medical Center

Sites in Durham, NC

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1497

Shown on this page

Current sort

Live official records

Conditions: Acquired Antithrombin Deficiency
Interventions: Human plasma derived antithrombin, Placebo; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Interventions: Placebo Matching Mitapivat, Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • La Jolla, California • Oakland, California + 7 more

Conditions: Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions: Placebo Matching Mitapivat, Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more

Conditions: Pyruvate Kinase Deficiency
Interventions: Not listed
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 10 more

Conditions: Memory, Delayed
Interventions: Deep Brain Stimulation, Memory and spatial navigation tasks, Physiological Signals, Questionnaires and Assessments; Device · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Myelodysplastic Syndromes
Interventions: Tebapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Lakewood, California • Los Angeles, California • Redlands, California + 6 more

Conditions: Multiple Myeloma
Interventions: JNJ-79635322, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 765423, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Gainesville, Florida • Ocala, Florida + 11 more

Conditions: Urinary Bladder Neoplasms
Interventions: Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy; Biological · Drug · Radiation
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 28
States / cities: Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more

Conditions: Breast Cancer, Metastatic
Interventions: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more

Conditions: Multiple Myeloma
Interventions: Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D, Ramantamig; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more

Conditions: Hyperkalemia
Interventions: Patiromer; Drug
Lead sponsor: Vifor Pharma, Inc.; Industry
Eligibility: 0 Years to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more

About this Duke University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Duke University Medical Center in Durham, NC as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Duke University Medical Center

Filter and sort this campus

Live official records

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

Pyruvate Kinase Deficiency Global Longitudinal Registry

Neural Correlates of Real World Spatial Navigation in Humans

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

About this Duke University Medical Center institution page